Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

Unleash Metformin

(2014) Wenya R. Lu et al.   ANNALS OF PHARMACOTHERAPY

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria

(2014) Yukihiro Chino et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

(2014) Benjamin M. Scirica et al.   CIRCULATION

Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

(2014) Paul Nyirjesy et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)

(2014) Matthew R. Weir et al.   CURRENT MEDICAL RESEARCH AND OPINION

LADA and CARDS: A Prospective Study of Clinical Outcome in Established Adult-Onset Autoimmune Diabetes

(2014) Mohammed Iqbal Hawa et al.   DIABETES CARE

Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes

(2014) Michaela Diamant et al.   DIABETES CARE

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes

(2014) Julio Rosenstock et al.   DIABETES CARE

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment

(2014) P.-H. Groop et al.   DIABETES OBESITY & METABOLISM

The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial

(2014) W. Lane et al.   DIABETES OBESITY & METABOLISM

High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7)

(2014) Simona Zampetti et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis

(2014) Bernard Charbonnel et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment

(2014) Amy G. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial

(2013) Bruce Neal et al.   AMERICAN HEART JOURNAL

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

(2013) John B. Buse et al.   ANNALS OF INTERNAL MEDICINE

Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials

(2013) Faramarz Ismail-Beigi et al.   ANNALS OF INTERNAL MEDICINE

Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

(2013) Despoina Vasilakou et al.   ANNALS OF INTERNAL MEDICINE

Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

(2013) D. M. Nathan et al.   DIABETES CARE

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea

(2013) Guntram Schernthaner et al.   DIABETES CARE

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

(2013) W. B. White et al.   DIABETES OBESITY & METABOLISM

Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis

(2013) O. J. Phung et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis

(2013) S. Goring et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials

(2013) M. Monami et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

(2013) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

(2013) Kristina M. Johnsson et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Pioglitazone use and the risk of bladder cancer

(2013) Hsin-Wei Kuo et al.   KAOHSIUNG JOURNAL OF MEDICAL SCIENCES

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

(2013) William T Cefalu et al.   LANCET

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

(2013) Michael Roden et al.   Lancet Diabetes & Endocrinology

Pioglitazone and bladder cancer: a propensity score matched cohort study

(2012) Li Wei et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature

(2012) R. Balena et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2012) K. Stenlöf et al.   DIABETES OBESITY & METABOLISM

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs

(2012) H. M. Colhoun et al.   DIABETOLOGIA

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects

(2012) Ele Ferrannini et al.   Nature Reviews Endocrinology

A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials

(2011) Giovanni Musso et al.   ANNALS OF MEDICINE

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial

(2011) M. A. Nauck et al.   DIABETES CARE

Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency

(2011) K. J. Lipska et al.   DIABETES CARE

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study

(2011) E. Bosi et al.   DIABETES OBESITY & METABOLISM

Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes

(2011) P. K. Shah et al.   DIABETES OBESITY & METABOLISM

A Stepwise Approach to Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Basal Insulin Treatment Failure

(2011) Mayer Davidson et al.   Endocrine Practice

Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease?

(2011) Helen J. Nye et al.   NEPHRON CLINICAL PRACTICE

Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes

(2010) J. M. Gaziano et al.   DIABETES CARE

Pioglitazone Use in Combination with Insulin in the Prospective Pioglitazone Clinical Trial in Macrovascular Events Study (PROactive19)

(2010) Bernard Charbonnel et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Review: Metformin: Potential benefits and use in chronic kidney disease

(2010) HELEN L PILMORE   NEPHROLOGY

U-500 Regular Insulin: Clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients

(2009) M. B. Davidson et al.   DIABETES CARE

Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications

(2009) George L. Bakris et al.   KIDNEY INTERNATIONAL

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE